Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Genmab A/SNASDAQ: GMAB

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA declines year over year

Q2 FY2026 EBITDA of $431M fell 3.8% year over year. Sequentially, it rose 130.9% from the prior quarter. Over 3 fiscal years it compounded at -43.3% a year.

Context

  • EBITDA amounted to 35.9% of revenue in FY2025, down 9.1 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 15 analysts of $1.89B (+41.7%) for the fiscal year ending Dec 2026, a step up from the -86.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$431M+130.9% QoQ
Last fiscal yearDec 2025
$1.34B-86.2% YoY
LTMJun 2026
$1.22B— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.8%+0.1%+3.8 pp
1 year-86.2%+41.7%+127.9 pp
3-year CAGR-43.3%+26.3%+69.6 pp
5-year CAGR+16.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

Mixed currencies · from the income statement

Latest · FY2025
1.34B USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • EBITDA amounts to 29.5% of revenue for GMAB, versus a peer median of 43.0%.
GMAB Competitors
EBITDA for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.07B USD+52.6%+43.2%35.5%
GMABGenmab A/SLTM Jun 2026$1.22B USD—-43.3%29.5%
EXELExelixis, Inc.LTM Jul 2026$1.05B USD+28.1%+53.4%43.0%
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M USD+154.3%—7.3%
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
ADCTADC Therapeutics S.A.LTM Mar 2026-$83.2M USD+13.7%—105.1%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$86.7M USD+32.0%——
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$185.11M USD+47.9%—48.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$419M USD-48.6%—358.1%
BNTXBioNTech SELTM Jun 2026-€941.06M EUR-2167.6%—35.6%
Peer median (excluding GMAB) —+30.0%+48.3%43.0%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.